Clinical Trials

    A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (HARMONi-3)

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Status: Enrolling

    ClinicalTrials.gov Number: NCT05899608

    Phone: 734.415.918

    Protocol Number: PRO00037983

    Description


    This is a Phase 3 Randomized, Controlled, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer. The primary endpoint is overall survival and key secondary endpoints include progression free survival. response and safety.